EGFR and non-small cell lung carcinoma: A recent study (the RELAY trial) demonstrated that ramucirumab in combination with erlotinib significantly improved PFS compared to erlotinib combined with placebo (19.4 vs. 12.4 months) in patients with untreated advanced EGFR-mutated NSCLC [20].